Resources

Contact us

BIOVECTRA offers a number of resources to help keep you up to date on industry trends and activities. Meet with us at events, follow us on LinkedIn, and explore the following resources for educational content.

  • Categories

Computer screen displaying an interview with BioVectra's Chief Commercial Officer. Includes a portrait of a person and text about supply and logistics.

DCAT WEEK 2022 Interview: Heather Delage

Interview

The location of a CDMO is always an important consideration by any sponsor organization considering its manufacturing strategy. BIOVECTRA’s facilities are located across several […]

Read More

An announcement about a new BIOMAN VFRC facility for mRNA vaccines. The webpage includes articles, images, and subscription options on a computer screen.

BIOVECTRA mRNA Vaccine and Biomanufacturing Facility Announced

Article

BIOVECTRA today announced plans for the development of a state-of-the-art facility specializing in the production and manufacturing of mRNA vaccines and therapeutics – one of the first of its kind in Canada. This exciting new capability will result from […]

Read More

Considerations for Microbial Fermentation: Single Use vs. Stainless Steel Fermenters site on desktop

Considerations for Microbial Fermentation: Single Use vs. Stainless Steel Fermenters

On-Demand Webinar

For decades, microbial fermentation has been used for the commercialization of biologics, with the fermentation of recombinant proteins such as insulin in stainless steel bioreactors as large as 100,000 L.[…]

Read More

Tour BIOVECTRA’s Microbial Fermentation Production Suites

Tour BIOVECTRA’s Microbial Fermentation Production Suites

Virtual Tour

For decades, microbial fermentation has been used for the commercialization of biologics, with the fermentation of recombinant proteins such as insulin in stainless steel bioreactors as large as 100,000 L. […]

Take Tour

Single-use fermenters for the production of biologics Book Cover

Single-Use Fermenters for the Production of Biologics

White Paper

Large-scale single-use fermentation technology using aerobic microbial expression systems offers an excellent complement to stainless steel bioreactors for clinical-to-commercial scale production of recombinant proteins. […]

Read More

Leveraging Existing Technologies with New Dedicated Facilities for mRNA Projects Document On desktop

Leveraging Existing Technologies with New Dedicated Facilities for mRNA Projects

Article

The development and production of mRNA therapeutics and vaccines requires expertise in both chemical synthesis and microbial fermentation.  […]

Read More

Looking to Another 50 Years of Growth Site on desktop

Looking to Another 50 Years of Growth

Interview

For the final interview of the Road to 50 States road trip campaign, Oliver Technow and Heather Delage of BIOVECTRA met with Nigel at CPhI in Milan to discuss the company’s unique capability to offer both small and large molecule biologic products to their clients. […]

Read More

White paper document

Challenges and Opportunities in High-Potency Pharmaceuticals Manufacturing

White Paper

High-potency drugs derived from natural products command a large and growing market share in the pharmaceutical industry. The rich diversity of potent natural products necessitates a range of manufacturing demands.  […]

Read More

Facilitating Clinical Manufacturing of Recombinant Proteins with Large-Scale Single-Use Fermentation Technology Article On Desktop

Facilitating Clinical Manufacturing of Recombinant Proteins with Large-Scale Single-Use Fermentation Technology

Article

BIOVECTRA’s Scott Doncaster, Neil Morrison, and Cameron Graham discuss the company’s addition of single-use fermenter technology […]

Read More

Enabling Commercial Manufacturing for Highly Complex Small Molecule Drugs Through Process Engineering and Technological Innovation Article Illustration

Enabling Commercial Manufacturing for Highly Complex Small Molecule Drugs Through Process Engineering and Technological Innovation

Article

Much of the innovation occurring in the pharmaceutical industry today is achieved by smaller pharma/biotech firms with limited commercial manufacturing experience […]

Read More

Supporting Client Projects for CDMO Success Document

Supporting Client Projects for CDMO Success

Article

The production of increasingly complex small molecule APIs is challenging drug makers. CDMOs with multiple capabilities are needed to develop efficient routes to synthesize these […]

Read More

SEO plus – Test

  • 20+ years at GSK, leading R&D activities on multiple vaccine programs
  • Recently held positions in industry include: Senior Director (Function Head), Protein Biochemistry; Director, Antigen Design & Prototype Production; and, Associate Director, Antigen Design and Protein Characterization.
  • Key areas of expertise are:
    • Process development of protein Biologics/Recombinant Antigens
    • Recombinant protein expression (mammalian, insect, yeast, bacterial)
    • Production/design of Viral Vectors, mRNA vaccines, Bacterial outer membrane vesicles
    • Protein Engineering and Structural Biology
    • Defining quality attributes, biophysical characterization of proteins, and analytical strategy
  • Post graduate degrees in Functional Genomics (Université Laval) and Bioinformatics (MIT); M. Sc. Microbiology and Immunology (Laval).
  • 25+ Patent & 5 Scientific Publications

Normand Blais – Senior Director Development & Innovation, Biologics

  • 20+ years at GSK, leading R&D activities on multiple vaccine programs
  • Recently held positions in industry include: Senior Director (Function Head), Protein Biochemistry; Director, Antigen Design & Prototype Production; and, Associate Director, Antigen Design and Protein Characterization.
  • Key areas of expertise are:
    • Process development of protein Biologics/Recombinant Antigens
    • Recombinant protein expression (mammalian, insect, yeast, bacterial)
    • Production/design of Viral Vectors, mRNA vaccines, Bacterial outer membrane vesicles
    • Protein Engineering and Structural Biology
    • Defining quality attributes, biophysical characterization of proteins, and analytical strategy
  • Post graduate degrees in Functional Genomics (Université Laval) and Bioinformatics (MIT); M. Sc. Microbiology and Immunology (Laval).
  • 25+ Patent & 5 Scientific Publications

Oliver Technow - Chief Executive Officer

  • Industry Master Degree from Frankfurt Chamber of Commerce, Frankfurt Germany.
  • More than 20 years of global pharmaceutical industry experience.
  • Held numerous leadership positions in commercial development, marketing and brand management, and lifecycle management and has extensive product launch and market access expertise in Europe and North America.
  • In 1997, joined Eisai GmbH in Frankfurt, Germany and in 2002, was appointed Director, CNS Business Unit; in 2006, was appointed Vice President, Head of Global Marketing for Eisai Inc. in Woodcliff Lake, NJ;  in 2011, was appointed Vice President, Established Products Business Unit; in 2013, was appointed President & General Manager for Eisai Limited in Mississauga, ON.
  • Appointed President of BIOVECTRA Inc., December 10, 2015.
  • Board Director for BIOTECanada
  • Member of the Steering Council of Innovative Medicines Canada (IMC)
  • In 2017, appointed to the Government of Canada’s Health/Bio-sciences Strategic Economic Table
  • In November 2019, promoted to Chief Executive Officer at BIOVECTRA
  • In June 2020, named new Chair of PEI BioAlliance Board of Directors